

Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β -Cells by Peroxisome Proliferator-Activated Receptor (PPAR)- γ Signaling

Possible Mechanism for the GIP Resistance in Type 2 Diabetes

Dhananjay Gupta, Mina Peshavaria, Navjot Monga, Thomas L. Jetton, and Jack L. Leahy

OBJECTIVE—We previously showed that peroxisome proliferator-activated receptor (PPAR)- γ in β -cells regulates *pdx-1* transcription through a functional PPAR response element (PPRE). Gene Bank blast for a homologous nucleotide sequence revealed the same PPRE within the rat glucose-dependent insulinotropic polypeptide receptor (GIP-R) promoter sequence. We investigated the role of PPAR γ in GIP-R transcription.

RESEARCH DESIGN AND METHODS—Chromatin immunoprecipitation assay, siRNA, and luciferase gene transcription assay in INS-1 cells were performed. Islet GIP-R expression and immunohistochemistry studies were performed in pancreas-specific PPAR γ knockout mice (PANC PPAR $\gamma^{-/-}$), normoglycemic 60% pancreatectomy rats (Px), normoglycemic and hyperglycemic Zucker fatty (ZF) rats, and mouse islets incubated with troglitazone.

RESULTS—In vitro studies of INS-1 cells confirmed that PPAR γ binds to the putative PPRE sequence and regulates GIP-R transcription. In vivo verification was shown by a 70% reduction in GIP-R protein expression in islets from PANC PPAR $\gamma^{-/-}$ mice and a twofold increase in islets of 14-day post-60% Px Sprague-Dawley rats that hyperexpress β -cell PPAR γ . Thiazolidinedione activation (72 h) of this pathway in normal mouse islets caused a threefold increase of GIP-R protein and a doubling of insulin secretion to 16.7 mmol/l glucose/10 nmol/l GIP. Islets from obese normoglycemic ZF rats had twofold increased PPAR γ and GIP-R protein levels versus lean rats, with both lowered by two-thirds in ZF rats made hyperglycemic by 60% Px.

CONCLUSIONS—Our studies have shown physiologic and pharmacologic regulation of GIP-R expression in β -cells by PPAR γ signaling. Also disruption of this signaling pathway may account for the lowered β -cell GIP-R expression and resulting GIP resistance in type 2 diabetes. *Diabetes* 59:1445–1450, 2010

From the Division of Endocrinology, Diabetes, and Metabolism and the Department of Medicine, University of Vermont, Burlington, Vermont.

Corresponding author: Jack L. Leahy, jleahy@uvm.edu.

Received 8 November 2009 and accepted 12 March 2010. Published ahead of print at <http://diabetes.diabetesjournals.org> on 23 March 2010. DOI: 10.2337/db09-1655.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid incretin hormone that binds to a seven-transmembrane G-protein-coupled receptor (GIP-R) that is expressed in numerous tissues including islet β -cells and α -cells (1,2). Its best-known actions in β -cells are to augment meal-related insulin secretion and over the long-term to increase proinsulin synthesis and β -cell proliferation and survival (3,4). Several downstream signaling pathways from the β -cell GIP-R have been characterized. In contrast, little is known about GIP-R expression. A cAMP response element and SP1 and SP2 transcription factor binding sites are present in the 5' promoter region, but no physiologic modulators are known (4,5). As such, our understanding of GIP physiology is based solely on regulated GIP secretion and rapid metabolism to modulate its cellular actions. The one exception is the lowered number of β -cell GIP-R in animals (6,7) and humans (8) with type 2 diabetes, and the resulting GIP resistance (9), which results from hyperglycemia through an unknown mechanism (7,10).

Our laboratory has studied the biologic actions of PPAR γ in β -cells and shown transcriptional regulation of the prodifferentiation transcription factor Pdx-1 (11,12). As part of our studies, we identified the PPAR response element (PPRE) within the *pdx-1* promoter (12). We now report finding the same PPRE sequence within the rat GIP-R promoter, followed by confirming physiologic and pharmacologic regulation of GIP-R transcription in β -cells by PPAR γ . Also, we provide evidence that the lowered β -cell GIP-R expression in hyperglycemic rats may result from impaired PPAR γ expression.

RESEARCH DESIGN AND METHODS

Animal models. All protocols were in accordance with the principles of laboratory animal care and were approved by the University of Vermont Institutional Animal Care and Use Committee.

60% pancreatectomy (Px) rats. The 5-week-old male Sprague-Dawley rats, and Zucker fatty (ZF, *fa/fa*) or lean controls (ZL, *fa/+* or *+/+*), underwent 60% Px or sham Px as previously described (11,13).

PANC PPAR $\gamma^{-/-}$ mice. Mice with PPAR γ deficiency restricted to pancreatic epithelium were generated by crossing Pdx-1 Cre mice and mice with two floxed PPAR γ alleles as previously detailed (12,14). Controls were littermate Cre negative PPAR γ floxed mice.

INS-1 cells. INS-1 (832/13) cells were cultured as previously described (11,12).




FIG. 1. Experiments in INS-1 cells. **A:** Chromatin immunoprecipitation assay to assess PPAR γ binding to the putative PPRE on the *GIP-R* gene. Chromatin fragments (300–500 bp length) were generated. Representative gel showing chromatin preparations from two separate experiments immunoprecipitated with rabbit polyclonal anti-PPAR γ (lanes 2 and 3) or the negative control nonimmune serum (lanes 4 and 5). Lane 1 is nonimmunoprecipitated DNA. Results show the expected 213-bp PCR product with the anti-PPAR γ and input DNA, but not the control serum. **B:** PPAR γ siRNA. INS-1 cells underwent transfections with siRNA duplexes against the rat *PPAR γ* gene or scrambled siRNA duplexes. Cells were cultured with media that contained 10 μ M troglitazone or DMSO for 72 h, and the isolated RNA was assessed for *GIP-R* mRNA levels by RT-PCR. Representative gels show scrambled siRNA cells cultured with DMSO (lane 1), scrambled siRNA cells cultured with troglitazone (lane 2), siRNA cells cultured with troglitazone (lane 3), and siRNA cells cultured with DMSO (lane 4). Cyclophilin B mRNA was used as an internal control. **C and D:** Luciferase reporter transcription assay. INS-1 cells were transfected with wild-type or mutated pTAL-PPRE-rat *GIP-R* vectors, and 24 h post-transfection, the cells were treated with 10 μ M troglitazone or DMSO for 24 h. WT = wild-type rat *GIP-R* PPRE (CCCATG-G-AGGTCA). Mut-1 = mutation of the 5' DR1 half-site of the rat *GIP-R* PPRE (AAAATA-G-AGGTCA). Mut-2 = mutation of the 3' DR2 half-site of the rat *GIP-R* PPRE (CCCATG-G-ATTTA). **C** shows the relative basal luciferase activity (DMSO-treated cells) compared with the wild-type rat *GIP-R* PPRE construct as means \pm SEM of three separate experiments. **D** shows the troglitazone treatment effect on luciferase reporter activity of the wild-type and mutated *GIP-R* PPREs. * $P < 0.015$ vs. DMSO-cultured wild-type *GIP-R* PPRE cells. # $P < 0.001$ vs. troglitazone cultured wild-type *GIP-R* PPRE cells.

Experimental methods. See the online appendix, available at <http://diabetes.diabetesjournals.org/cgi/content/full/db09-1655/DC1>.

Statistical analysis. Data are presented as mean \pm SEM. Each data point from the animal studies was obtained from an individual rat or mouse. Statistical significance was determined by the unpaired Student's *t* test or two-way ANOVA.

RESULTS

GIP-R promoter PPRE. We previously identified a functional PPRE in the mouse *pdx-1* promoter (12). Gene Bank blast for this nucleotide sequence found a 100% identical sequence in the rat *GIP-R* promoter at positions –871 to –883 from the transcription start site (Gene Bank: AF050667) (supplemental Fig. 1A, available in the online appendix). MatInspector software (15) uncovered analogous sequences in the mouse and human *GIP-R* promoters (supplemental Fig. 1B).

INS-1 cell studies. Studies were performed in rat-derived INS-1 cells to confirm functionality of this putative PPRE. PPAR γ binding was determined with the chromatin immunoprecipitation assay. Flanking primer pairs for a 213-bp PCR product that included the *GIP-R* PPRE (schema in supplemental Fig. 2A) generated the correct-sized PCR

band with input DNA and PPAR γ antibody-precipitated DNA, whereas only faint bands were observed with non-immune serum (Fig. 1A). Representative negative and positive controls are shown in supplemental Fig. 2.

PPAR γ regulation of *GIP-R* expression was tested using four pooled siRNA duplexes against PPAR γ in INS-1 cells that cause a 75% decrease in PPAR γ protein (11). Cells were treated with troglitazone or vehicle for 72 h (Fig. 1B). *GIP-R* mRNA band intensity was markedly lowered in the PPAR γ siRNA cells (lanes 1 and 4). Troglitazone doubled it in control cells (lane 2), whereas the increase was eliminated when troglitazone and the PPAR γ siRNA duplexes were used together (lane 3).

PPAR γ regulation of *GIP-R* transcription was confirmed with a luciferase reporter gene assay that used a wild-type rat *GIP-R* promoter fragment and also those containing mutations in the DR1 and DR2 hexamers of the *GIP-R* PPRE (Mut-1 and Mut-2 fragments), subcloned into the pTAL luciferase reporter vector. The DR1 and DR2 mutations both lowered basal luciferase activity (Mut-1 63 \pm 9% of wild-type *GIP-R*, $P < 0.015$; Mut-2 38 \pm 8% of wild-type *GIP-R*, $P < 0.002$) (Fig. 1C). Also, 24-h incubation with




FIG. 2. Islet GIP-R mRNA and protein expression, and pancreas immunostaining for GIP-R, in 8-week-old male PANC $\text{PPAR}\gamma^{-/-}$ mice with a pancreas-specific knockout of $\text{PPAR}\gamma$ (KO) and littermate floxed control mice (Cre $^{-}$). Representative gels showing PCR products for islet GIP-R and cyclophilin (A) and immunoblots for GIP-R and β -actin from two separate PANC $\text{PPAR}\gamma^{-/-}$ and two floxed control mice (B) are shown. C: Representative islet fields on a pancreas section from a male PANC $\text{PPAR}\gamma^{-/-}$ and floxed control mouse stained with rabbit GIP-R antiserum in the left panels, costained with insulin antiserum in the middle panels, and insulin antiserum alone in the right panels. The scale bar is 20 μm . (A high-quality digital representation of this figure is available in the online issue.)

troglitazone (Fig. 1D) stimulated expression of the wild-type GIP-R construct ($162 \pm 8\%$ of vehicle-treated wild-type cells, $P < 0.002$), whereas this effect was absent with both mutations.

In vivo studies. In vivo testing of $\text{PPAR}\gamma$ regulation of β -cell GIP-R expression was carried out using PANC $\text{PPAR}\gamma^{-/-}$ mice that have a pancreas-specific deletion of $\text{PPAR}\gamma$ from a Cre/loxP recombinase system with Cre driven by the *pdx-1* promoter (14). We previously reported that 8-week-old male PANC $\text{PPAR}\gamma^{-/-}$ mice are modestly hyperglycemic, with a normal β -cell mass and normal-appearing pancreas histology and islet cytoarchitecture (12). The current studies confirmed the expected defect in GIP-R expression (Fig. 2A, mRNA; Fig. 2B, protein $29 \pm 5\%$ of control, $P < 0.0001$) in isolated islets from these mice. Immunofluorescence studies of pancreas sections showed markedly lowered GIP-R staining in islet β -cells and non- β -cells of PANC $\text{PPAR}\gamma^{-/-}$ mice versus control mice (Fig. 2C).

Analogous studies were performed in normoglycemic Sprague-Dawley rats 14 days after 60% Px when islet nuclear $\text{PPAR}\gamma$ expression is 2.5-fold increased (11). Comparable increases in GIP-R mRNA (Fig. 3A) and protein (Fig. 3B, 1.9 ± 0.2 -fold of sham, $P < 0.02$) were found in Px versus sham rat islets. Also, GIP-R staining intensity was increased in islet β -cells and non- β -cells versus the sham rats (Fig. 3C).

Troglitazone studies. Thiazolidinedione (TZD) stimulation of GIP-R expression was tested by incubating normal mouse islets for 72 h with troglitazone or vehicle. Trogli-

tazone caused a near-tripling of the GIP-R protein level (supplemental Figs. 3A and B, 2.7 ± 0.4 -fold of DMSO islets, $P < 0.02$). Also the insulin response to 16.7 mmol/l glucose/10 nmol/l GIP peptide was nearly doubled ($P < 0.05$), whereas insulin responses to 2.8 mmol/l glucose with or without GIP peptide, and to high glucose alone, were unchanged (supplemental Fig. 3C).

Hyperglycemic rats. We speculated that impaired $\text{PPAR}\gamma$ expression caused the β -cell GIP-R depletion in animal models of type 2 diabetes (6,7). Accordingly, we performed $\text{PPAR}\gamma$ and GIP-R Western blots on islet extracts from 3-week postsurgery 60% Px and sham-operated ZF and ZL rats, based on our report that Px ZF rats are hyperglycemic (~ 15 mmol/l) with the same degree of obesity and serum levels of nonesterified fatty acids and GIP as normoglycemic sham ZF rats (13). Figure 4 shows that islet $\text{PPAR}\gamma$ and GIP-R protein levels are doubled in the sham ZF versus sham ZL rats (1.9 ± 0.1 -fold, $P < 0.001$; 2.2 ± 0.3 -fold, $P < 0.01$, respectively). In contrast, both are lowered by 60% in Px (hyperglycemic) ZF islets versus the sham (normoglycemic) ZF islets (0.7 ± 0.1 -fold and 0.8 ± 0.1 -fold of sham ZL islets, respectively).

DISCUSSION

We used in vitro and in vivo techniques to show for the first time that GIP-R transcription in β -cells is regulated by $\text{PPAR}\gamma$. Also, that pharmacologic activation of $\text{PPAR}\gamma$ by TZDs induces the same effect resulting in greater GIP potentiation of glucose-induced insulin secretion. These




FIG. 3. Islet GIP-R mRNA and protein expression, and pancreas immunostaining for GIP-R, in 14-day postsurgery 60% Px and sham-operated Sprague-Dawley rats. Representative gels showing PCR products for islet GIP-R and cyclophilin (A) and immunoblots for GIP-R and β -actin from two separate Px and sham rats (B) are shown. C: Representative islet fields on pancreas section from a Px rat and a sham-operated rat stained with rabbit GIP-R antiserum in the left panels and costained with insulin antiserum in the right panels. The scale bar is 20 μ m. (A high-quality digital representation of this figure is available in the online issue.)

results add to our prior studies of PPAR γ signaling in β -cells that showed 40% of adult mouse islet *pdx-1* expression is PPAR γ regulated (11,12) by our now finding a second gene with the identical PPRE and functional characteristics.

There are several noteworthy implications to these results. First, Pdx-1 is considered the most important transcription factor in β -cells related to its essential role for normal β -cell function, viability, and compensation capacity (16). Also, studies of incretin receptor knockout mice and in vivo usage of GIP-R peptide agonists have demonstrated a necessary role for GIP in normal mealtime glucose tolerance and insulin secretion (17,18). Clinical trials have found a particularly high success rate of TZDs in pre-diabetes and early type 2 diabetes, with the mechanism believed to be the peripheral insulin sensitization lowering the drive for insulin secretion (so-called “ β -cell rest”) (19). However, given the importance of the identified PPAR γ -regulated genes in β -cells, our results raise the possibility that direct PPAR γ -mediated effects on β -cells also account for some of the clinical benefits. Indeed, others have shown a direct effect of TZDs to restore Pdx-1 levels and reduce endoplasmic stress in islets from diabetic rats (20).

Second, there is the possibility we have uncovered an unknown feature of incretin physiology, i.e., variable GIP-R expression, related to our finding increased islet GIP-R expression in two rat models of β -cell compensation from unrelated causes: reduced β -cell mass in 60% Px Sprague-Dawley rats (21) and mutated leptin receptors resulting in obesity, insulin resistance, and hyperlipidemia

in ZF rats (13). This shared observation is particularly interesting, since there is no precedence for GIP-R hyperexpression except in the adrenocortical tumors of some individuals with Cushing’s syndrome (22). Also, our finding that the GIP-R hyperexpression in both models was paralleled by increased β -cell expression of PPAR γ (11; Fig. 4) is consistent with the main conclusions of this study regarding PPAR γ regulation of β -cell GIP-R expression. On the other hand, an in vitro study reported PPAR α regulates β -cell GIP-R expression and speculated this effect occurs in vivo related to the β -cell fatty acid load (23). This mechanism seems unlikely in the 60% Px Sprague-Dawley rats, since serum triglyceride and free fatty acid levels are unchanged post-Px in lean rats (13,21), plus islet PPAR α expression is reduced (13). In contrast, ZF rats are markedly hyperlipidemic (13), making this a potential mechanism. Also the lack of a post-Px increase in PPAR γ and GIP-R expression in ZL rats (Fig. 4) may reflect the different times of study—3 weeks post-Px in ZL rats versus 2 weeks post-Px in Sprague-Dawley rats.

The third implication of our results is our speculation that aberrant PPAR γ signaling is a new mechanism for the lowered β -cell GIP-R expression and GIP resistance in animal and human type 2 diabetes (6–9). Hyperglycemia causes this effect in animals (7,10), but no mechanistic details are known except for a study that reported accelerated GIP-R degradation in islets cultured at high glucose conditions (24). Figure 4 supports our proposal by showing parallel reductions in islet expression of PPAR γ and GIP-R in the hyperglycemic ZF rats. However, Px ZF rats




FIG. 4. Islet GIP-R and PPAR γ protein expression in Zucker fatty (*fa/fa*) and Zucker lean (*fa/+*, *+/+*) rats 3 weeks post 60% Px or sham-Px surgery. **A:** Representative immunoblots for GIP-R, PPAR γ , and β -actin in islet extracts from 60% Px or sham-operated ZF and ZL rats. **B and C:** Graphs showing % means \pm SEM band intensities for GIP-R and PPAR γ , respectively, relative to sham-operated ZL islets using data from four separate experiments. * $P < 0.005$ ZF sham vs. ZL sham islets. # $P < 0.005$ ZF sham vs. ZF Px islets.

also have a reduction in islet PPAR α mRNA expression (13), so the exact mechanism is unknown. A related issue is the lowered β -cell expression for the other incretin hormone receptor (GLP-1) in animals and humans with type 2 diabetes (7,8). However, the molecular mechanism is likely different from the GIP-R depletion based on the study by Xu et al. (7) that performed 96-h glucose infusions in conscious rats and found islet GLP-1R mRNA levels fell 50%, whereas GIP-R mRNA levels modestly increased, plus they noted the same divergence in 2-day high glucose cultured islets. Also, it is likely that the lowered islet incretin receptor expression in type 2 diabetes is multifactorial, with recent interest in disrupted TCF7L2 signaling (8). Thus, our results suggest that β -cell PPAR γ regulation of GIP-R expression is a newly identified feature of incretin (patho)-physiology and TZD therapeutics. Also the lowered islet PPAR γ expression in Px ZF rats (glycemia 15 mmol/l) may provide a new understanding why TZD therapy is so powerful in pre-diabetes and early type 2 diabetes as opposed to the more modest efficacy with advanced type 2 diabetes (19,25).

In summary, GIP-R is a newly described PPAR γ -regulated gene in β -cells. Expression of both genes is increased in rat models with β -cell adaptation to diverse stimuli. Also, TZDs augment GIP potentiation of glucose-induced insulin secretion through this mechanism. In contrast, this expression system is downregulated in diabetic rats. As such, our studies have uncovered a new mechanism for regulatory control of the β -cell GIP-R expression and may have added a new understanding to incretin (patho)-physiology and TZD therapy.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants DK56818 (J.L.L.) and DK68329 (T.L.J.), the Juvenile Diabetes Research Foundation (M.P.), and the Iacocca Foundation (M.P.).

No potential conflicts of interest relevant to this article were reported.

The authors would like to thank Dr. Richard Mortenson and Dr. Sheng Zhong Duan (University of Michigan) for the PANC PPAR $\gamma^{-/-}$ mouse model, Dr. Timothy Kieffer (University of British Columbia) for the GIP-R antiserum, and Dr. Michael Wolfe (Boston University) for GIP-R promoter constructs.

REFERENCES

- Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. *Endocrinology* 1993;133:2861–2870
- Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. *Diabetes* 1996;45:257–261
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology* 2007;132:2131–2157
- McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). *Vitam Horm* 2009;80: 409–471
- Boylan MO, Jepeal LI, Wolfe MM. Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene. *Peptides* 1999;20:219–228
- Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. *Diabetes* 2001;50:1004–1011
- Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King

- GL, Weir GC, Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. *Diabetes* 2007;56:1551–1558
8. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. *Hum Mol Genet* 2009;18:2388–2399
 9. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. *Diabetologia* 2002;45:1111–1119
 10. Piteau S, Olver A, Kim SJ, Winter K, Pospisilik JA, Lynn F, Manhart S, Demuth HU, Speck M, Pederson RA, McIntosh CH. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. *Biochem Biophys Res Commun* 2007;362:1007–1012
 11. Moibi JA, Gupta D, Jetton TL, Peshavaria M, Desai R, Leahy JL. Peroxisome proliferator-activated receptor- α regulates expression of PDX-1 and NKX6.1 in INS-1 cells. *Diabetes* 2007;56:88–95
 12. Gupta D, Jetton TL, Mortensen RM, Duan SZ, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor- γ response element in the mouse pdx-1 promoter. *J Biol Chem* 2008;283:32462–32470
 13. Delghingaro-Augusto V, Nolan CJ, Gupta D, Jetton TL, Latour MG, Peshavaria M, Madiraju SR, Joly E, Peyot ML, Prentki M, Leahy J. Islet beta cell failure in the 60% pancreatectomized obese hyperlipidaemic Zucker fatty rat: severe dysfunction with altered glycerolipid metabolism without steatosis or a falling beta cell mass. *Diabetologia* 2009;52:1122–1132
 14. Ivashchenko CY, Duan SZ, Usher MG, Mortensen RM. PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced pancreatitis. *Am J Physiol* 2007;293:G319–G326
 15. Lemay DG, Hwang DH. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. *J Lipid Res* 2006;47:1583–1587
 16. Ackermann AM, Gannon M. Molecular regulation of pancreatic β -cell mass development, maintenance, and expansion. *J Mol Endocrinol* 2007;38:193–206
 17. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. *J Clin Invest* 1996;98:2440–2445
 18. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. *Proc Natl Acad Sci U S A* 1999;96:14843–14847
 19. Leahy JL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. *Curr Diab Rep* 2009;9:215–220
 20. Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garney JC, Deering TG, Keller SR, Maier B, Mirmira RG. Peroxisome proliferator-activated receptor γ activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. *Mol Cell Biol* 2009;29:2053–2067
 21. Liu YQ, Nevin PW, Leahy JL. Mechanism of β -cell adaptation that preserves normoinsulinemia and normoglycemia in 60% pancreatectomy rats. *Am J Physiol* 2000;279:E68–E73
 22. N'Diaye N, Tremblay J, Hamet P, De Herder WW, Lacroix A. Adrenocortical overexpression of gastric inhibitory polypeptide receptors underlies food-dependent Cushing's syndrome. *J Clin Endocrinol Metab* 1998;83:2781–2785
 23. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CH, Pederson RA. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. *FASEB J* 2003;17:91–93
 24. Zhou J, Livak MF, Bernier M, Muller DC, Carlson OD, Elahi D, Maudsley S, Egan JM. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. *Am J Physiol* 2007;293:E538–E547
 25. Yki-Jarvinen H. Thiazolidinediones. *N Engl J Med* 2004;351:1106–1118